Exact Sciences should be bought on weakness, says Craig-HallumCraig-Hallum analyst Kevin Ellich notes that Exact Sciences are down following the short report issued by Citron Research. The analyst believes the issues raised in the short report are relatively consistent with the past issues raised on Exact Sciences over the years. While Citron has raised some interesting points, rehashed some of the old short thesis and caused a lot of volatility in the stock, Ellich adds, he would be a buyer on weakness. The analyst reiterates a Buy rating and $35 price target on the shares. |